Medical Care
Global Fibromyalgia Therapeutics Market Research Report 2025
- Jul 08, 25
- ID: 347684
- Pages: 94
- Figures: 100
- Views: 1
The global market for Fibromyalgia Therapeutics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Fibromyalgia Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fibromyalgia Therapeutics.
The Fibromyalgia Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Fibromyalgia Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Fibromyalgia Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Eli Lilly
Actavis
Merck Sharp and Dohme
Daiichi Sankyo
Innovative Med Concepts
Meda
Meiji Seika
Switch Biotech
Theravance
Zynerba Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. (TNXP)
Daiichi Sankyo
Forest Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Pierre Fabre Mdicament
Segment by Type
Cymbalta (Duloxetine)
Savella (Milnacipran)
Lyrica (Pregabalin)
Pancuronium
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Fibromyalgia Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Fibromyalgia Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fibromyalgia Therapeutics.
The Fibromyalgia Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Fibromyalgia Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Fibromyalgia Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Eli Lilly
Actavis
Merck Sharp and Dohme
Daiichi Sankyo
Innovative Med Concepts
Meda
Meiji Seika
Switch Biotech
Theravance
Zynerba Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. (TNXP)
Daiichi Sankyo
Forest Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Pierre Fabre Mdicament
Segment by Type
Cymbalta (Duloxetine)
Savella (Milnacipran)
Lyrica (Pregabalin)
Pancuronium
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Fibromyalgia Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Fibromyalgia Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Cymbalta (Duloxetine)
1.2.3 Savella (Milnacipran)
1.2.4 Lyrica (Pregabalin)
1.2.5 Pancuronium
1.2.6 Others
1.3 Market by Application
1.3.1 Global Fibromyalgia Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Fibromyalgia Therapeutics Market Perspective (2020-2031)
2.2 Global Fibromyalgia Therapeutics Growth Trends by Region
2.2.1 Global Fibromyalgia Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Fibromyalgia Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Fibromyalgia Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Fibromyalgia Therapeutics Market Dynamics
2.3.1 Fibromyalgia Therapeutics Industry Trends
2.3.2 Fibromyalgia Therapeutics Market Drivers
2.3.3 Fibromyalgia Therapeutics Market Challenges
2.3.4 Fibromyalgia Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Fibromyalgia Therapeutics Players by Revenue
3.1.1 Global Top Fibromyalgia Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Fibromyalgia Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Fibromyalgia Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Fibromyalgia Therapeutics Revenue
3.4 Global Fibromyalgia Therapeutics Market Concentration Ratio
3.4.1 Global Fibromyalgia Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Fibromyalgia Therapeutics Revenue in 2024
3.5 Global Key Players of Fibromyalgia Therapeutics Head office and Area Served
3.6 Global Key Players of Fibromyalgia Therapeutics, Product and Application
3.7 Global Key Players of Fibromyalgia Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Fibromyalgia Therapeutics Breakdown Data by Type
4.1 Global Fibromyalgia Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Fibromyalgia Therapeutics Forecasted Market Size by Type (2026-2031)
5 Fibromyalgia Therapeutics Breakdown Data by Application
5.1 Global Fibromyalgia Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Fibromyalgia Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Fibromyalgia Therapeutics Market Size (2020-2031)
6.2 North America Fibromyalgia Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Fibromyalgia Therapeutics Market Size by Country (2020-2025)
6.4 North America Fibromyalgia Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Fibromyalgia Therapeutics Market Size (2020-2031)
7.2 Europe Fibromyalgia Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Fibromyalgia Therapeutics Market Size by Country (2020-2025)
7.4 Europe Fibromyalgia Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Fibromyalgia Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Fibromyalgia Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Fibromyalgia Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Fibromyalgia Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Fibromyalgia Therapeutics Market Size (2020-2031)
9.2 Latin America Fibromyalgia Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Fibromyalgia Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Fibromyalgia Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Fibromyalgia Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Fibromyalgia Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Fibromyalgia Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Fibromyalgia Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Fibromyalgia Therapeutics Introduction
11.1.4 Pfizer Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.1.5 Pfizer Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Fibromyalgia Therapeutics Introduction
11.2.4 Eli Lilly Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.2.5 Eli Lilly Recent Development
11.3 Actavis
11.3.1 Actavis Company Details
11.3.2 Actavis Business Overview
11.3.3 Actavis Fibromyalgia Therapeutics Introduction
11.3.4 Actavis Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.3.5 Actavis Recent Development
11.4 Merck Sharp and Dohme
11.4.1 Merck Sharp and Dohme Company Details
11.4.2 Merck Sharp and Dohme Business Overview
11.4.3 Merck Sharp and Dohme Fibromyalgia Therapeutics Introduction
11.4.4 Merck Sharp and Dohme Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.4.5 Merck Sharp and Dohme Recent Development
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Company Details
11.5.2 Daiichi Sankyo Business Overview
11.5.3 Daiichi Sankyo Fibromyalgia Therapeutics Introduction
11.5.4 Daiichi Sankyo Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.5.5 Daiichi Sankyo Recent Development
11.6 Innovative Med Concepts
11.6.1 Innovative Med Concepts Company Details
11.6.2 Innovative Med Concepts Business Overview
11.6.3 Innovative Med Concepts Fibromyalgia Therapeutics Introduction
11.6.4 Innovative Med Concepts Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.6.5 Innovative Med Concepts Recent Development
11.7 Meda
11.7.1 Meda Company Details
11.7.2 Meda Business Overview
11.7.3 Meda Fibromyalgia Therapeutics Introduction
11.7.4 Meda Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.7.5 Meda Recent Development
11.8 Meiji Seika
11.8.1 Meiji Seika Company Details
11.8.2 Meiji Seika Business Overview
11.8.3 Meiji Seika Fibromyalgia Therapeutics Introduction
11.8.4 Meiji Seika Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.8.5 Meiji Seika Recent Development
11.9 Switch Biotech
11.9.1 Switch Biotech Company Details
11.9.2 Switch Biotech Business Overview
11.9.3 Switch Biotech Fibromyalgia Therapeutics Introduction
11.9.4 Switch Biotech Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.9.5 Switch Biotech Recent Development
11.10 Theravance
11.10.1 Theravance Company Details
11.10.2 Theravance Business Overview
11.10.3 Theravance Fibromyalgia Therapeutics Introduction
11.10.4 Theravance Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.10.5 Theravance Recent Development
11.11 Zynerba Pharmaceuticals
11.11.1 Zynerba Pharmaceuticals Company Details
11.11.2 Zynerba Pharmaceuticals Business Overview
11.11.3 Zynerba Pharmaceuticals Fibromyalgia Therapeutics Introduction
11.11.4 Zynerba Pharmaceuticals Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.11.5 Zynerba Pharmaceuticals Recent Development
11.12 Tonix Pharmaceuticals Holding Corp. (TNXP)
11.12.1 Tonix Pharmaceuticals Holding Corp. (TNXP) Company Details
11.12.2 Tonix Pharmaceuticals Holding Corp. (TNXP) Business Overview
11.12.3 Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Therapeutics Introduction
11.12.4 Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.12.5 Tonix Pharmaceuticals Holding Corp. (TNXP) Recent Development
11.13 Daiichi Sankyo
11.13.1 Daiichi Sankyo Company Details
11.13.2 Daiichi Sankyo Business Overview
11.13.3 Daiichi Sankyo Fibromyalgia Therapeutics Introduction
11.13.4 Daiichi Sankyo Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.13.5 Daiichi Sankyo Recent Development
11.14 Forest Pharmaceuticals, Inc.
11.14.1 Forest Pharmaceuticals, Inc. Company Details
11.14.2 Forest Pharmaceuticals, Inc. Business Overview
11.14.3 Forest Pharmaceuticals, Inc. Fibromyalgia Therapeutics Introduction
11.14.4 Forest Pharmaceuticals, Inc. Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.14.5 Forest Pharmaceuticals, Inc. Recent Development
11.15 Boehringer Ingelheim GmbH
11.15.1 Boehringer Ingelheim GmbH Company Details
11.15.2 Boehringer Ingelheim GmbH Business Overview
11.15.3 Boehringer Ingelheim GmbH Fibromyalgia Therapeutics Introduction
11.15.4 Boehringer Ingelheim GmbH Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.15.5 Boehringer Ingelheim GmbH Recent Development
11.16 Pierre Fabre Mdicament
11.16.1 Pierre Fabre Mdicament Company Details
11.16.2 Pierre Fabre Mdicament Business Overview
11.16.3 Pierre Fabre Mdicament Fibromyalgia Therapeutics Introduction
11.16.4 Pierre Fabre Mdicament Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.16.5 Pierre Fabre Mdicament Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Fibromyalgia Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Cymbalta (Duloxetine)
1.2.3 Savella (Milnacipran)
1.2.4 Lyrica (Pregabalin)
1.2.5 Pancuronium
1.2.6 Others
1.3 Market by Application
1.3.1 Global Fibromyalgia Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Fibromyalgia Therapeutics Market Perspective (2020-2031)
2.2 Global Fibromyalgia Therapeutics Growth Trends by Region
2.2.1 Global Fibromyalgia Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Fibromyalgia Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Fibromyalgia Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Fibromyalgia Therapeutics Market Dynamics
2.3.1 Fibromyalgia Therapeutics Industry Trends
2.3.2 Fibromyalgia Therapeutics Market Drivers
2.3.3 Fibromyalgia Therapeutics Market Challenges
2.3.4 Fibromyalgia Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Fibromyalgia Therapeutics Players by Revenue
3.1.1 Global Top Fibromyalgia Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Fibromyalgia Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Fibromyalgia Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Fibromyalgia Therapeutics Revenue
3.4 Global Fibromyalgia Therapeutics Market Concentration Ratio
3.4.1 Global Fibromyalgia Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Fibromyalgia Therapeutics Revenue in 2024
3.5 Global Key Players of Fibromyalgia Therapeutics Head office and Area Served
3.6 Global Key Players of Fibromyalgia Therapeutics, Product and Application
3.7 Global Key Players of Fibromyalgia Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Fibromyalgia Therapeutics Breakdown Data by Type
4.1 Global Fibromyalgia Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Fibromyalgia Therapeutics Forecasted Market Size by Type (2026-2031)
5 Fibromyalgia Therapeutics Breakdown Data by Application
5.1 Global Fibromyalgia Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Fibromyalgia Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Fibromyalgia Therapeutics Market Size (2020-2031)
6.2 North America Fibromyalgia Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Fibromyalgia Therapeutics Market Size by Country (2020-2025)
6.4 North America Fibromyalgia Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Fibromyalgia Therapeutics Market Size (2020-2031)
7.2 Europe Fibromyalgia Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Fibromyalgia Therapeutics Market Size by Country (2020-2025)
7.4 Europe Fibromyalgia Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Fibromyalgia Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Fibromyalgia Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Fibromyalgia Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Fibromyalgia Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Fibromyalgia Therapeutics Market Size (2020-2031)
9.2 Latin America Fibromyalgia Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Fibromyalgia Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Fibromyalgia Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Fibromyalgia Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Fibromyalgia Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Fibromyalgia Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Fibromyalgia Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Fibromyalgia Therapeutics Introduction
11.1.4 Pfizer Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.1.5 Pfizer Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Fibromyalgia Therapeutics Introduction
11.2.4 Eli Lilly Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.2.5 Eli Lilly Recent Development
11.3 Actavis
11.3.1 Actavis Company Details
11.3.2 Actavis Business Overview
11.3.3 Actavis Fibromyalgia Therapeutics Introduction
11.3.4 Actavis Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.3.5 Actavis Recent Development
11.4 Merck Sharp and Dohme
11.4.1 Merck Sharp and Dohme Company Details
11.4.2 Merck Sharp and Dohme Business Overview
11.4.3 Merck Sharp and Dohme Fibromyalgia Therapeutics Introduction
11.4.4 Merck Sharp and Dohme Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.4.5 Merck Sharp and Dohme Recent Development
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Company Details
11.5.2 Daiichi Sankyo Business Overview
11.5.3 Daiichi Sankyo Fibromyalgia Therapeutics Introduction
11.5.4 Daiichi Sankyo Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.5.5 Daiichi Sankyo Recent Development
11.6 Innovative Med Concepts
11.6.1 Innovative Med Concepts Company Details
11.6.2 Innovative Med Concepts Business Overview
11.6.3 Innovative Med Concepts Fibromyalgia Therapeutics Introduction
11.6.4 Innovative Med Concepts Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.6.5 Innovative Med Concepts Recent Development
11.7 Meda
11.7.1 Meda Company Details
11.7.2 Meda Business Overview
11.7.3 Meda Fibromyalgia Therapeutics Introduction
11.7.4 Meda Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.7.5 Meda Recent Development
11.8 Meiji Seika
11.8.1 Meiji Seika Company Details
11.8.2 Meiji Seika Business Overview
11.8.3 Meiji Seika Fibromyalgia Therapeutics Introduction
11.8.4 Meiji Seika Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.8.5 Meiji Seika Recent Development
11.9 Switch Biotech
11.9.1 Switch Biotech Company Details
11.9.2 Switch Biotech Business Overview
11.9.3 Switch Biotech Fibromyalgia Therapeutics Introduction
11.9.4 Switch Biotech Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.9.5 Switch Biotech Recent Development
11.10 Theravance
11.10.1 Theravance Company Details
11.10.2 Theravance Business Overview
11.10.3 Theravance Fibromyalgia Therapeutics Introduction
11.10.4 Theravance Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.10.5 Theravance Recent Development
11.11 Zynerba Pharmaceuticals
11.11.1 Zynerba Pharmaceuticals Company Details
11.11.2 Zynerba Pharmaceuticals Business Overview
11.11.3 Zynerba Pharmaceuticals Fibromyalgia Therapeutics Introduction
11.11.4 Zynerba Pharmaceuticals Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.11.5 Zynerba Pharmaceuticals Recent Development
11.12 Tonix Pharmaceuticals Holding Corp. (TNXP)
11.12.1 Tonix Pharmaceuticals Holding Corp. (TNXP) Company Details
11.12.2 Tonix Pharmaceuticals Holding Corp. (TNXP) Business Overview
11.12.3 Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Therapeutics Introduction
11.12.4 Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.12.5 Tonix Pharmaceuticals Holding Corp. (TNXP) Recent Development
11.13 Daiichi Sankyo
11.13.1 Daiichi Sankyo Company Details
11.13.2 Daiichi Sankyo Business Overview
11.13.3 Daiichi Sankyo Fibromyalgia Therapeutics Introduction
11.13.4 Daiichi Sankyo Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.13.5 Daiichi Sankyo Recent Development
11.14 Forest Pharmaceuticals, Inc.
11.14.1 Forest Pharmaceuticals, Inc. Company Details
11.14.2 Forest Pharmaceuticals, Inc. Business Overview
11.14.3 Forest Pharmaceuticals, Inc. Fibromyalgia Therapeutics Introduction
11.14.4 Forest Pharmaceuticals, Inc. Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.14.5 Forest Pharmaceuticals, Inc. Recent Development
11.15 Boehringer Ingelheim GmbH
11.15.1 Boehringer Ingelheim GmbH Company Details
11.15.2 Boehringer Ingelheim GmbH Business Overview
11.15.3 Boehringer Ingelheim GmbH Fibromyalgia Therapeutics Introduction
11.15.4 Boehringer Ingelheim GmbH Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.15.5 Boehringer Ingelheim GmbH Recent Development
11.16 Pierre Fabre Mdicament
11.16.1 Pierre Fabre Mdicament Company Details
11.16.2 Pierre Fabre Mdicament Business Overview
11.16.3 Pierre Fabre Mdicament Fibromyalgia Therapeutics Introduction
11.16.4 Pierre Fabre Mdicament Revenue in Fibromyalgia Therapeutics Business (2020-2025)
11.16.5 Pierre Fabre Mdicament Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Fibromyalgia Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Cymbalta (Duloxetine)
Table 3. Key Players of Savella (Milnacipran)
Table 4. Key Players of Lyrica (Pregabalin)
Table 5. Key Players of Pancuronium
Table 6. Key Players of Others
Table 7. Global Fibromyalgia Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Fibromyalgia Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Fibromyalgia Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Fibromyalgia Therapeutics Market Share by Region (2020-2025)
Table 11. Global Fibromyalgia Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Fibromyalgia Therapeutics Market Share by Region (2026-2031)
Table 13. Fibromyalgia Therapeutics Market Trends
Table 14. Fibromyalgia Therapeutics Market Drivers
Table 15. Fibromyalgia Therapeutics Market Challenges
Table 16. Fibromyalgia Therapeutics Market Restraints
Table 17. Global Fibromyalgia Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Fibromyalgia Therapeutics Market Share by Players (2020-2025)
Table 19. Global Top Fibromyalgia Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fibromyalgia Therapeutics as of 2024)
Table 20. Ranking of Global Top Fibromyalgia Therapeutics Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Fibromyalgia Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Fibromyalgia Therapeutics, Headquarters and Area Served
Table 23. Global Key Players of Fibromyalgia Therapeutics, Product and Application
Table 24. Global Key Players of Fibromyalgia Therapeutics, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Fibromyalgia Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Fibromyalgia Therapeutics Revenue Market Share by Type (2020-2025)
Table 28. Global Fibromyalgia Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Fibromyalgia Therapeutics Revenue Market Share by Type (2026-2031)
Table 30. Global Fibromyalgia Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Fibromyalgia Therapeutics Revenue Market Share by Application (2020-2025)
Table 32. Global Fibromyalgia Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Fibromyalgia Therapeutics Revenue Market Share by Application (2026-2031)
Table 34. North America Fibromyalgia Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Fibromyalgia Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Fibromyalgia Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Fibromyalgia Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Fibromyalgia Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Fibromyalgia Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Fibromyalgia Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Fibromyalgia Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Fibromyalgia Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Fibromyalgia Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Fibromyalgia Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Fibromyalgia Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Fibromyalgia Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Fibromyalgia Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Fibromyalgia Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 49. Pfizer Company Details
Table 50. Pfizer Business Overview
Table 51. Pfizer Fibromyalgia Therapeutics Product
Table 52. Pfizer Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 53. Pfizer Recent Development
Table 54. Eli Lilly Company Details
Table 55. Eli Lilly Business Overview
Table 56. Eli Lilly Fibromyalgia Therapeutics Product
Table 57. Eli Lilly Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 58. Eli Lilly Recent Development
Table 59. Actavis Company Details
Table 60. Actavis Business Overview
Table 61. Actavis Fibromyalgia Therapeutics Product
Table 62. Actavis Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 63. Actavis Recent Development
Table 64. Merck Sharp and Dohme Company Details
Table 65. Merck Sharp and Dohme Business Overview
Table 66. Merck Sharp and Dohme Fibromyalgia Therapeutics Product
Table 67. Merck Sharp and Dohme Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 68. Merck Sharp and Dohme Recent Development
Table 69. Daiichi Sankyo Company Details
Table 70. Daiichi Sankyo Business Overview
Table 71. Daiichi Sankyo Fibromyalgia Therapeutics Product
Table 72. Daiichi Sankyo Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 73. Daiichi Sankyo Recent Development
Table 74. Innovative Med Concepts Company Details
Table 75. Innovative Med Concepts Business Overview
Table 76. Innovative Med Concepts Fibromyalgia Therapeutics Product
Table 77. Innovative Med Concepts Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 78. Innovative Med Concepts Recent Development
Table 79. Meda Company Details
Table 80. Meda Business Overview
Table 81. Meda Fibromyalgia Therapeutics Product
Table 82. Meda Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 83. Meda Recent Development
Table 84. Meiji Seika Company Details
Table 85. Meiji Seika Business Overview
Table 86. Meiji Seika Fibromyalgia Therapeutics Product
Table 87. Meiji Seika Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 88. Meiji Seika Recent Development
Table 89. Switch Biotech Company Details
Table 90. Switch Biotech Business Overview
Table 91. Switch Biotech Fibromyalgia Therapeutics Product
Table 92. Switch Biotech Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 93. Switch Biotech Recent Development
Table 94. Theravance Company Details
Table 95. Theravance Business Overview
Table 96. Theravance Fibromyalgia Therapeutics Product
Table 97. Theravance Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 98. Theravance Recent Development
Table 99. Zynerba Pharmaceuticals Company Details
Table 100. Zynerba Pharmaceuticals Business Overview
Table 101. Zynerba Pharmaceuticals Fibromyalgia Therapeutics Product
Table 102. Zynerba Pharmaceuticals Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 103. Zynerba Pharmaceuticals Recent Development
Table 104. Tonix Pharmaceuticals Holding Corp. (TNXP) Company Details
Table 105. Tonix Pharmaceuticals Holding Corp. (TNXP) Business Overview
Table 106. Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Therapeutics Product
Table 107. Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 108. Tonix Pharmaceuticals Holding Corp. (TNXP) Recent Development
Table 109. Daiichi Sankyo Company Details
Table 110. Daiichi Sankyo Business Overview
Table 111. Daiichi Sankyo Fibromyalgia Therapeutics Product
Table 112. Daiichi Sankyo Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 113. Daiichi Sankyo Recent Development
Table 114. Forest Pharmaceuticals, Inc. Company Details
Table 115. Forest Pharmaceuticals, Inc. Business Overview
Table 116. Forest Pharmaceuticals, Inc. Fibromyalgia Therapeutics Product
Table 117. Forest Pharmaceuticals, Inc. Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 118. Forest Pharmaceuticals, Inc. Recent Development
Table 119. Boehringer Ingelheim GmbH Company Details
Table 120. Boehringer Ingelheim GmbH Business Overview
Table 121. Boehringer Ingelheim GmbH Fibromyalgia Therapeutics Product
Table 122. Boehringer Ingelheim GmbH Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 123. Boehringer Ingelheim GmbH Recent Development
Table 124. Pierre Fabre Mdicament Company Details
Table 125. Pierre Fabre Mdicament Business Overview
Table 126. Pierre Fabre Mdicament Fibromyalgia Therapeutics Product
Table 127. Pierre Fabre Mdicament Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 128. Pierre Fabre Mdicament Recent Development
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
Table 132. Authors List of This Report
List of Figures
Figure 1. Fibromyalgia Therapeutics Picture
Figure 2. Global Fibromyalgia Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Fibromyalgia Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Cymbalta (Duloxetine) Features
Figure 5. Savella (Milnacipran) Features
Figure 6. Lyrica (Pregabalin) Features
Figure 7. Pancuronium Features
Figure 8. Others Features
Figure 9. Global Fibromyalgia Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Fibromyalgia Therapeutics Market Share by Application: 2024 VS 2031
Figure 11. Hospital Case Studies
Figure 12. Clinic Case Studies
Figure 13. Others Case Studies
Figure 14. Fibromyalgia Therapeutics Report Years Considered
Figure 15. Global Fibromyalgia Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Fibromyalgia Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Fibromyalgia Therapeutics Market Share by Region: 2024 VS 2031
Figure 18. Global Fibromyalgia Therapeutics Market Share by Players in 2024
Figure 19. Global Top Fibromyalgia Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fibromyalgia Therapeutics as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Fibromyalgia Therapeutics Revenue in 2024
Figure 21. North America Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Fibromyalgia Therapeutics Market Share by Country (2020-2031)
Figure 23. United States Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Fibromyalgia Therapeutics Market Share by Country (2020-2031)
Figure 27. Germany Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Fibromyalgia Therapeutics Market Share by Region (2020-2031)
Figure 35. China Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Fibromyalgia Therapeutics Market Share by Country (2020-2031)
Figure 43. Mexico Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Fibromyalgia Therapeutics Market Share by Country (2020-2031)
Figure 47. Turkey Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Pfizer Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 51. Eli Lilly Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 52. Actavis Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 53. Merck Sharp and Dohme Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 54. Daiichi Sankyo Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 55. Innovative Med Concepts Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 56. Meda Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 57. Meiji Seika Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 58. Switch Biotech Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 59. Theravance Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 60. Zynerba Pharmaceuticals Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 61. Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 62. Daiichi Sankyo Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 63. Forest Pharmaceuticals, Inc. Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 64. Boehringer Ingelheim GmbH Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 65. Pierre Fabre Mdicament Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Table 1. Global Fibromyalgia Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Cymbalta (Duloxetine)
Table 3. Key Players of Savella (Milnacipran)
Table 4. Key Players of Lyrica (Pregabalin)
Table 5. Key Players of Pancuronium
Table 6. Key Players of Others
Table 7. Global Fibromyalgia Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Fibromyalgia Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Fibromyalgia Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Fibromyalgia Therapeutics Market Share by Region (2020-2025)
Table 11. Global Fibromyalgia Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Fibromyalgia Therapeutics Market Share by Region (2026-2031)
Table 13. Fibromyalgia Therapeutics Market Trends
Table 14. Fibromyalgia Therapeutics Market Drivers
Table 15. Fibromyalgia Therapeutics Market Challenges
Table 16. Fibromyalgia Therapeutics Market Restraints
Table 17. Global Fibromyalgia Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Fibromyalgia Therapeutics Market Share by Players (2020-2025)
Table 19. Global Top Fibromyalgia Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fibromyalgia Therapeutics as of 2024)
Table 20. Ranking of Global Top Fibromyalgia Therapeutics Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Fibromyalgia Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Fibromyalgia Therapeutics, Headquarters and Area Served
Table 23. Global Key Players of Fibromyalgia Therapeutics, Product and Application
Table 24. Global Key Players of Fibromyalgia Therapeutics, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Fibromyalgia Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Fibromyalgia Therapeutics Revenue Market Share by Type (2020-2025)
Table 28. Global Fibromyalgia Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Fibromyalgia Therapeutics Revenue Market Share by Type (2026-2031)
Table 30. Global Fibromyalgia Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Fibromyalgia Therapeutics Revenue Market Share by Application (2020-2025)
Table 32. Global Fibromyalgia Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Fibromyalgia Therapeutics Revenue Market Share by Application (2026-2031)
Table 34. North America Fibromyalgia Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Fibromyalgia Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Fibromyalgia Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Fibromyalgia Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Fibromyalgia Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Fibromyalgia Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Fibromyalgia Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Fibromyalgia Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Fibromyalgia Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Fibromyalgia Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Fibromyalgia Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Fibromyalgia Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Fibromyalgia Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Fibromyalgia Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Fibromyalgia Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 49. Pfizer Company Details
Table 50. Pfizer Business Overview
Table 51. Pfizer Fibromyalgia Therapeutics Product
Table 52. Pfizer Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 53. Pfizer Recent Development
Table 54. Eli Lilly Company Details
Table 55. Eli Lilly Business Overview
Table 56. Eli Lilly Fibromyalgia Therapeutics Product
Table 57. Eli Lilly Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 58. Eli Lilly Recent Development
Table 59. Actavis Company Details
Table 60. Actavis Business Overview
Table 61. Actavis Fibromyalgia Therapeutics Product
Table 62. Actavis Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 63. Actavis Recent Development
Table 64. Merck Sharp and Dohme Company Details
Table 65. Merck Sharp and Dohme Business Overview
Table 66. Merck Sharp and Dohme Fibromyalgia Therapeutics Product
Table 67. Merck Sharp and Dohme Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 68. Merck Sharp and Dohme Recent Development
Table 69. Daiichi Sankyo Company Details
Table 70. Daiichi Sankyo Business Overview
Table 71. Daiichi Sankyo Fibromyalgia Therapeutics Product
Table 72. Daiichi Sankyo Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 73. Daiichi Sankyo Recent Development
Table 74. Innovative Med Concepts Company Details
Table 75. Innovative Med Concepts Business Overview
Table 76. Innovative Med Concepts Fibromyalgia Therapeutics Product
Table 77. Innovative Med Concepts Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 78. Innovative Med Concepts Recent Development
Table 79. Meda Company Details
Table 80. Meda Business Overview
Table 81. Meda Fibromyalgia Therapeutics Product
Table 82. Meda Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 83. Meda Recent Development
Table 84. Meiji Seika Company Details
Table 85. Meiji Seika Business Overview
Table 86. Meiji Seika Fibromyalgia Therapeutics Product
Table 87. Meiji Seika Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 88. Meiji Seika Recent Development
Table 89. Switch Biotech Company Details
Table 90. Switch Biotech Business Overview
Table 91. Switch Biotech Fibromyalgia Therapeutics Product
Table 92. Switch Biotech Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 93. Switch Biotech Recent Development
Table 94. Theravance Company Details
Table 95. Theravance Business Overview
Table 96. Theravance Fibromyalgia Therapeutics Product
Table 97. Theravance Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 98. Theravance Recent Development
Table 99. Zynerba Pharmaceuticals Company Details
Table 100. Zynerba Pharmaceuticals Business Overview
Table 101. Zynerba Pharmaceuticals Fibromyalgia Therapeutics Product
Table 102. Zynerba Pharmaceuticals Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 103. Zynerba Pharmaceuticals Recent Development
Table 104. Tonix Pharmaceuticals Holding Corp. (TNXP) Company Details
Table 105. Tonix Pharmaceuticals Holding Corp. (TNXP) Business Overview
Table 106. Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Therapeutics Product
Table 107. Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 108. Tonix Pharmaceuticals Holding Corp. (TNXP) Recent Development
Table 109. Daiichi Sankyo Company Details
Table 110. Daiichi Sankyo Business Overview
Table 111. Daiichi Sankyo Fibromyalgia Therapeutics Product
Table 112. Daiichi Sankyo Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 113. Daiichi Sankyo Recent Development
Table 114. Forest Pharmaceuticals, Inc. Company Details
Table 115. Forest Pharmaceuticals, Inc. Business Overview
Table 116. Forest Pharmaceuticals, Inc. Fibromyalgia Therapeutics Product
Table 117. Forest Pharmaceuticals, Inc. Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 118. Forest Pharmaceuticals, Inc. Recent Development
Table 119. Boehringer Ingelheim GmbH Company Details
Table 120. Boehringer Ingelheim GmbH Business Overview
Table 121. Boehringer Ingelheim GmbH Fibromyalgia Therapeutics Product
Table 122. Boehringer Ingelheim GmbH Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 123. Boehringer Ingelheim GmbH Recent Development
Table 124. Pierre Fabre Mdicament Company Details
Table 125. Pierre Fabre Mdicament Business Overview
Table 126. Pierre Fabre Mdicament Fibromyalgia Therapeutics Product
Table 127. Pierre Fabre Mdicament Revenue in Fibromyalgia Therapeutics Business (2020-2025) & (US$ Million)
Table 128. Pierre Fabre Mdicament Recent Development
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
Table 132. Authors List of This Report
List of Figures
Figure 1. Fibromyalgia Therapeutics Picture
Figure 2. Global Fibromyalgia Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Fibromyalgia Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Cymbalta (Duloxetine) Features
Figure 5. Savella (Milnacipran) Features
Figure 6. Lyrica (Pregabalin) Features
Figure 7. Pancuronium Features
Figure 8. Others Features
Figure 9. Global Fibromyalgia Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Fibromyalgia Therapeutics Market Share by Application: 2024 VS 2031
Figure 11. Hospital Case Studies
Figure 12. Clinic Case Studies
Figure 13. Others Case Studies
Figure 14. Fibromyalgia Therapeutics Report Years Considered
Figure 15. Global Fibromyalgia Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Fibromyalgia Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Fibromyalgia Therapeutics Market Share by Region: 2024 VS 2031
Figure 18. Global Fibromyalgia Therapeutics Market Share by Players in 2024
Figure 19. Global Top Fibromyalgia Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fibromyalgia Therapeutics as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Fibromyalgia Therapeutics Revenue in 2024
Figure 21. North America Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Fibromyalgia Therapeutics Market Share by Country (2020-2031)
Figure 23. United States Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Fibromyalgia Therapeutics Market Share by Country (2020-2031)
Figure 27. Germany Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Fibromyalgia Therapeutics Market Share by Region (2020-2031)
Figure 35. China Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Fibromyalgia Therapeutics Market Share by Country (2020-2031)
Figure 43. Mexico Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Fibromyalgia Therapeutics Market Share by Country (2020-2031)
Figure 47. Turkey Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Fibromyalgia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Pfizer Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 51. Eli Lilly Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 52. Actavis Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 53. Merck Sharp and Dohme Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 54. Daiichi Sankyo Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 55. Innovative Med Concepts Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 56. Meda Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 57. Meiji Seika Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 58. Switch Biotech Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 59. Theravance Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 60. Zynerba Pharmaceuticals Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 61. Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 62. Daiichi Sankyo Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 63. Forest Pharmaceuticals, Inc. Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 64. Boehringer Ingelheim GmbH Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 65. Pierre Fabre Mdicament Revenue Growth Rate in Fibromyalgia Therapeutics Business (2020-2025)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Electrolytes for Lithium-Ion Batteries Market Research Report 2025
Jul 14, 25
Global Vanadium Products Market Research Report 2025
Jul 14, 25
Global High-purity Vanadium Oxide Market Research Report 2025
Jul 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232